Schizophrenia Clinical Trials in Miami, Florida
13 recruitingMiami, Florida
Showing 1–13 of 13 trials
Recruiting
Phase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Schizophrenia
Novartis Pharmaceuticals142 enrolled7 locationsNCT07467993
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled45 locationsNCT07379827
Recruiting
Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Schizophrenia
Eli Lilly and Company450 enrolled102 locationsNCT07410507
Recruiting
Phase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled19 locationsNCT07105111
Recruiting
Phase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences560 enrolled17 locationsNCT07227818
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled5 locationsNCT07184619
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Not Applicable
Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
Schizophrenia DisordersSchizoaffective DisorderPsychotic Disorder
University of California, San Diego201 enrolled3 locationsNCT07098169
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210